WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 463293
CAS#: 203787-91-1 (sodium)
Description: Salcaprozate sodium is an intestinal permeation enhancer (PE). It can be used as a delivery agent to promote the oral absorption of certain macromolecules with poor bioavailability such as insulin and heparin.
MedKoo Cat#: 463293
Name: Salcaprozate sodium
CAS#: 203787-91-1 (sodium)
Chemical Formula: C15H20NNaO4
Exact Mass:
Molecular Weight: 301.3178
Elemental Analysis: C, 59.79; H, 6.69; N, 4.65; Na, 7.63; O, 21.24
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Salcaprozate sodium; E 414; E414; E-414; SNAC; Salcaprozic acid, sodium salt;
IUPAC/Chemical Name: sodium 8-(2-hydroxybenzamido)octanoate
InChi Key: UOENJXXSKABLJL-UHFFFAOYSA-M
InChi Code: InChI=1S/C15H21NO4.Na/c17-13-9-6-5-8-12(13)15(20)16-11-7-3-1-2-4-10-14(18)19;/h5-6,8-9,17H,1-4,7,10-11H2,(H,16,20)(H,18,19);/q;+1/p-1
SMILES Code: Oc1c(C(NCCCCCCCC([O-])=O)=O)cccc1.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 301.3178 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Hossain S, Joyce P, Parrow A, Jõemetsa S, Höök F, Larsson P, Bergström CAS. Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers. Mol Pharm. 2020 Nov 2;17(11):4226-4240. doi: 10.1021/acs.molpharmaceut.0c00668. Epub 2020 Oct 8. PMID: 32960068.
2: Fattah S, Ismaiel M, Murphy B, Rulikowska A, Frias JM, Winter DC, Brayden DJ. Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers. Eur J Pharm Sci. 2020 Nov 1;154:105509. doi: 10.1016/j.ejps.2020.105509. Epub 2020 Aug 8. PMID: 32777258.
3: Twarog C, Liu K, O'Brien PJ, Dawson KA, Fattal E, Illel B, Brayden DJ. A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C10). Eur J Pharm Biopharm. 2020 Jul;152:95-107. doi: 10.1016/j.ejpb.2020.04.023. Epub 2020 May 6. PMID: 32387703.
4: Chiang PC, Deshmukh G, Liu J, Nagapudi K, Chen JZ, Valle N, Li R, Plise EG, Durk MR. Evaluating the Pharmacokinetics and Systemic Effects of a Permeability Enhancer Sodium N-[8-(2-hydroxybenzoyl)amino] Caprylate in Rats. J Pharm Sci. 2020 Aug;109(8):2629-2636. doi: 10.1016/j.xphs.2020.04.016. Epub 2020 Apr 28. PMID: 32360544.
5: Li Y, Zhu C. Development and In Vitro and In Vivo Evaluation of Microspheres Containing Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate for the Oral Delivery of Berberine Hydrochloride. Molecules. 2020 Apr 23;25(8):1957. doi: 10.3390/molecules25081957. PMID: 32340157; PMCID: PMC7221516.
6: Antza C, Nirantharakumar K, Doundoulakis I, Tahrani AA, Toulis KA. The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2019 Aug 22;13:2985-2996. doi: 10.2147/DDDT.S166765. PMID: 31686781; PMCID: PMC6709822.
7: Bucheit JD, Pamulapati LG, Carter N, Malloy K, Dixon DL, Sisson EM. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. Diabetes Technol Ther. 2020 Jan;22(1):10-18. doi: 10.1089/dia.2019.0185. Epub 2019 Oct 1. PMID: 31436480.
8: Bækdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW. Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. Clin Pharmacokinet. 2019 Sep;58(9):1193-1203. doi: 10.1007/s40262-019-00756-2. PMID: 30945118; PMCID: PMC6719321.
9: Twarog C, Fattah S, Heade J, Maher S, Fattal E, Brayden DJ. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10). Pharmaceutics. 2019 Feb 13;11(2):78. doi: 10.3390/pharmaceutics11020078. PMID: 30781867; PMCID: PMC6410172.
10: Granhall C, Donsmark M, Blicher TM, Golor G, Søndergaard FL, Thomsen M, Bækdal TA. Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. Clin Pharmacokinet. 2019 Jun;58(6):781-791. doi: 10.1007/s40262-018-0728-4. PMID: 30565096.
11: Li Y, Yang D, Zhu C. Impact of Sodium N-[8-(2-Hydroxybenzoyl)amino]-caprylate on Intestinal Permeability for Notoginsenoside R1 and Salvianolic Acids in Caco-2 Cells Transport and Rat Pharmacokinetics. Molecules. 2018 Nov 16;23(11):2990. doi: 10.3390/molecules23112990. PMID: 30453465; PMCID: PMC6278436.
12: Brito A, Habeych E, Silva-Zolezzi I, Galaffu N, Allen LH. Methods to assess vitamin B12 bioavailability and technologies to enhance its absorption. Nutr Rev. 2018 Oct 1;76(10):778-792. doi: 10.1093/nutrit/nuy026. PMID: 29931214.
13: Bækdal TA, Breitschaft A, Navarria A, Hansen CW. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. Expert Opin Drug Metab Toxicol. 2018 Aug;14(8):869-877. doi: 10.1080/17425255.2018.1488965. Epub 2018 Jun 30. PMID: 29897249.
14: Baekdal TA, Thomsen M, Kupčová V, Hansen CW, Anderson TW. Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment. J Clin Pharmacol. 2018 Oct;58(10):1314-1323. doi: 10.1002/jcph.1131. Epub 2018 Apr 25. PMID: 29693715; PMCID: PMC6175428.
15: Miyata K, Ukawa M, Mohri K, Fujii K, Yamada M, Tanishita S, Higashitarumi S, Ishizaki S, Kumagai H, Ochiai K, Hiwatari KI, Tsubaki K, Shigeno K, Tobita E, Kobayashi H, Sakuma S. Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery. Bioconjug Chem. 2018 May 16;29(5):1748-1755. doi: 10.1021/acs.bioconjchem.8b00185. Epub 2018 Apr 18. PMID: 29648441.
16: Granhall C, Søndergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. Clin Pharmacokinet. 2018 Dec;57(12):1571-1580. doi: 10.1007/s40262-018-0649-2. PMID: 29623579; PMCID: PMC6267549.
17: McCartney F, Gleeson JP, Brayden DJ. Safety concerns over the use of intestinal permeation enhancers: A mini-review. Tissue Barriers. 2016 Apr 12;4(2):e1176822. doi: 10.1080/21688370.2016.1176822. PMID: 27358756; PMCID: PMC4910835.
18: Bittner B, McIntyre C, Tian H, Tang K, Shah N, Phuapradit W, Ahmed H, Chokshi H, Infeld M, Fotaki N, Ma H, Portron A, Jordan P, Schmidt J. Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC). Pharmazie. 2012 Mar;67(3):233-41. PMID: 22530305.
19: Bittner B, McIntyre C, Jordan P, Schmidt J. Drug-drug interaction study between a novel oral ibandronate formulation and metformin. Arzneimittelforschung. 2011;61(12):707-13. doi: 10.1055/s-0031-1300591. PMID: 22282958.
20: Castelli MC, Wong DF, Friedman K, Riley MG. Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects. Clin Ther. 2011 Jul;33(7):934-45. doi: 10.1016/j.clinthera.2011.05.088. Epub 2011 Jul 1. PMID: 21722960.
